ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

ASLNDelisted Stock  USD 0.60  0.03  4.76%   
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
New research collaboration will explore the differentiation of eblasakimabs mechanism of action versus biologic therapies for atopic dermatitis , dupilumab and lebrikizumab.The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of ebla

Read at finance.yahoo.com
Yahoo News
  

Aslan Pharmaceuticals Fundamental Analysis

We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Aslan Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Aslan Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aslan Pharmaceuticals Related Equities

CTMXCytomX Therapeutics   12.84   
0%
100.0%
LYRALyra Therapeutics   10.53   
0%
82.0%
ANEBAnebulo Pharmaceuticals   7.64   
0%
59.0%
ADAGAdagene   6.39   
0%
49.0%
NAMSNewAmsterdam Pharma   1.73   
0%
13.0%
ACRVAcrivon Therapeutics,   0.13   
0%
1.0%
AGIOAgios Pharm   0.02   
0%
1.0%
IVAInventiva   0.38   
2.0%
0%
ACHLAchilles Therapeutics   0.93   
7.0%
0%
AVTEAerovate Therapeutics   1.50   
11.0%
0%
GPCRStructure Therapeutics   2.03   
15.0%
0%
ASMBAssembly Biosciences   2.09   
16.0%
0%
CMPXCompass Therapeutics   2.41   
18.0%
0%
CGEMCullinan Oncology   2.81   
21.0%
0%
TILInstil Bio   2.86   
22.0%
0%
GLUEMonte Rosa   3.52   
27.0%
0%
IOBTIO Biotech   4.44   
34.0%
0%
MLYSMineralys Therapeutics,   4.60   
35.0%
0%
ERASErasca   4.95   
38.0%
0%
ANTXAN2 Therapeutics   6.25   
48.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Consideration for investing in Aslan Stock

If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Transaction History
View history of all your transactions and understand their impact on performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins